These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The effect of botulinum toxin A on skin flap survival in rats. Kim YS; Roh TS; Lee WJ; Yoo WM; Tark KC Wound Repair Regen; 2009; 17(3):411-7. PubMed ID: 19660050 [TBL] [Abstract][Full Text] [Related]
24. Botulinum toxin type A affects cell cycle distribution of fibroblasts derived from hypertrophic scar. Zhibo X; Miaobo Z J Plast Reconstr Aesthet Surg; 2008 Sep; 61(9):1128-9. PubMed ID: 18555763 [No Abstract] [Full Text] [Related]
25. Time of exposure and time of testing in developmental neurotoxicology. Rodier PM Neurotoxicology; 1986; 7(2):69-76. PubMed ID: 3537863 [No Abstract] [Full Text] [Related]
26. Potency of the botulinum toxin product CNBTX-A significantly exceeds labeled units in standard potency test. Hunt T; Clarke K J Am Acad Dermatol; 2008 Mar; 58(3):517-8. PubMed ID: 18280358 [No Abstract] [Full Text] [Related]
27. I have read that Botox now comes with a warning. How safe is it for removing wrinkles? Johns Hopkins Med Lett Health After 50; 2009 Sep; 21(7):8. PubMed ID: 19827169 [No Abstract] [Full Text] [Related]
28. Re: Pickett, the botulinum toxin LD50 potency assay — another chapter, another mystery. Stephens ML Altern Lab Anim; 2012 Dec; 40(6):346-7; author reply 347-8. PubMed ID: 23447844 [No Abstract] [Full Text] [Related]
29. Potency equivalence of botulinum toxin preparations. Hambleton P; Pickett AM J R Soc Med; 1994 Nov; 87(11):719. PubMed ID: 7837204 [No Abstract] [Full Text] [Related]
30. Botox: beyond cosmetic fixes. The procedure that revolutionized wrinkle treatment has myriad medical uses, many still experimental. What's the evidence? Harv Womens Health Watch; 2009 Sep; 17(1):1-3. PubMed ID: 19928628 [No Abstract] [Full Text] [Related]
31. Palmar hyperhidrosis: long-term follow-up of nine children and adolescents treated with botulinum toxin type A. Coutinho dos Santos LH; Gomes AM; Giraldi S; Abagge KT; Marinoni LP Pediatr Dermatol; 2009; 26(4):439-44. PubMed ID: 19689521 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Ascher B; Rzany BJ; Grover R Dermatol Surg; 2009 Oct; 35(10):1478-86. PubMed ID: 19686365 [TBL] [Abstract][Full Text] [Related]
33. Using botulinum toxin to treat diabetic foot pain. Kaufman JL; Karceski S Neurology; 2009 Apr; 72(17):e82-5. PubMed ID: 19398700 [No Abstract] [Full Text] [Related]
35. [Parabola bioassays in the comparison of drug effects (author's transl)]. Xu DZ Zhongguo Yao Li Xue Bao; 1981 Jun; 2(2):73-8. PubMed ID: 6461216 [No Abstract] [Full Text] [Related]
36. [Median lethal dose and its significance test]. Bravo-Becherelle MA Salud Publica Mex; 1971; 13(2):213-6. PubMed ID: 4935806 [No Abstract] [Full Text] [Related]
37. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298 [TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. Siddiqui NY; Amundsen CL; Visco AG; Myers ER; Wu JM J Urol; 2009 Dec; 182(6):2799-804. PubMed ID: 19837427 [TBL] [Abstract][Full Text] [Related]